Selected research
Industry Research
Hemophilia Drugs Industry Research Report 2026
Market perspective
The global Hemophilia Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Hemophilia Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Hemophilia Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Hemophilia Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Hemophilia Drugs include Pfizer, Bayer, Swedish Orphan Biovitrum, Spark Therapeutics, Sangamo Biosciences, Octapharma, Grifols, F. Hoffmann-La Roche and Dimension Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Hemophilia Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hemophilia Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hemophilia Drugs Market by Company
Pfizer
Bayer
Swedish Orphan Biovitrum
Spark Therapeutics
Sangamo Biosciences
Octapharma
Grifols
F. Hoffmann-La Roche
Dimension Therapeutics
CSL Behring
Catalyst Biosciences
BioMarin
Baxalta
Alnylam Pharmaceuticals
Hemophilia Drugs Segment by Type
Von Willebrand Disease
Hemophilia A
Hemophilia B
Inhibitors
Hemophilia Drugs Segment by Application
Recombinant Therapies
Plasma-Derived Therapies
Hemophilia Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hemophilia Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Von Willebrand Disease
- Hemophilia A
- Hemophilia B
- Inhibitors
Applications
- Recombinant Therapies
- Plasma-Derived Therapies
Companies covered
- Pfizer
- Bayer
- Swedish Orphan Biovitrum
- Spark Therapeutics
- Sangamo Biosciences
- Octapharma
- Grifols
- F. Hoffmann-La Roche
- Dimension Therapeutics
- CSL Behring
- Catalyst Biosciences
- BioMarin
- Baxalta
- Alnylam Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hemophilia Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Von Willebrand Disease
- 2.2.3 Hemophilia A
- 2.2.4 Hemophilia B
- 2.2.5 Inhibitors
- 2.3 Hemophilia Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Recombinant Therapies
- 2.3.3 Plasma-Derived Therapies
- 2.4 Assumptions and Limitations
3 Hemophilia Drugs Breakdown Data by Type
- 3.1 Global Hemophilia Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Hemophilia Drugs Forecasted Market Size by Type (2027-2032)
4 Hemophilia Drugs Breakdown Data by Application
- 4.1 Global Hemophilia Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Hemophilia Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hemophilia Drugs Market Perspective (2021-2032)
- 5.2 Global Hemophilia Drugs Growth Trends by Region
- 5.2.1 Global Hemophilia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hemophilia Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Hemophilia Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Hemophilia Drugs Market Dynamics
- 5.3.1 Hemophilia Drugs Industry Trends
- 5.3.2 Hemophilia Drugs Market Drivers
- 5.3.3 Hemophilia Drugs Market Challenges
- 5.3.4 Hemophilia Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hemophilia Drugs Players by Revenue
- 6.1.1 Global Top Hemophilia Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Hemophilia Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Hemophilia Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hemophilia Drugs Head Office and Area Served
- 6.4 Global Hemophilia Drugs Players, Product Type & Application
- 6.5 Global Hemophilia Drugs Manufacturers Established Date
- 6.6 Global Hemophilia Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hemophilia Drugs Market Size (2021-2032)
- 7.2 North America Hemophilia Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hemophilia Drugs Market Size by Country (2021-2026)
- 7.4 North America Hemophilia Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hemophilia Drugs Market Size (2021-2032)
- 8.2 Europe Hemophilia Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hemophilia Drugs Market Size by Country (2021-2026)
- 8.4 Europe Hemophilia Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hemophilia Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Hemophilia Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hemophilia Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hemophilia Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hemophilia Drugs Market Size (2021-2032)
- 10.2 South America Hemophilia Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hemophilia Drugs Market Size by Country (2021-2026)
- 10.4 South America Hemophilia Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hemophilia Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Hemophilia Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hemophilia Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hemophilia Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in Hemophilia Drugs Business (2021-2026)
- 12.1.4 Pfizer Hemophilia Drugs Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 Bayer
- 12.2.1 Bayer Company Information
- 12.2.2 Bayer Business Overview
- 12.2.3 Bayer Revenue in Hemophilia Drugs Business (2021-2026)
- 12.2.4 Bayer Hemophilia Drugs Product Portfolio
- 12.2.5 Bayer Recent Developments
- 12.3 Swedish Orphan Biovitrum
- 12.3.1 Swedish Orphan Biovitrum Company Information
- 12.3.2 Swedish Orphan Biovitrum Business Overview
- 12.3.3 Swedish Orphan Biovitrum Revenue in Hemophilia Drugs Business (2021-2026)
- 12.3.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
- 12.3.5 Swedish Orphan Biovitrum Recent Developments
- 12.4 Spark Therapeutics
- 12.4.1 Spark Therapeutics Company Information
- 12.4.2 Spark Therapeutics Business Overview
- 12.4.3 Spark Therapeutics Revenue in Hemophilia Drugs Business (2021-2026)
- 12.4.4 Spark Therapeutics Hemophilia Drugs Product Portfolio
- 12.4.5 Spark Therapeutics Recent Developments
- 12.5 Sangamo Biosciences
- 12.5.1 Sangamo Biosciences Company Information
- 12.5.2 Sangamo Biosciences Business Overview
- 12.5.3 Sangamo Biosciences Revenue in Hemophilia Drugs Business (2021-2026)
- 12.5.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio
- 12.5.5 Sangamo Biosciences Recent Developments
- 12.6 Octapharma
- 12.6.1 Octapharma Company Information
- 12.6.2 Octapharma Business Overview
- 12.6.3 Octapharma Revenue in Hemophilia Drugs Business (2021-2026)
- 12.6.4 Octapharma Hemophilia Drugs Product Portfolio
- 12.6.5 Octapharma Recent Developments
- 12.7 Grifols
- 12.7.1 Grifols Company Information
- 12.7.2 Grifols Business Overview
- 12.7.3 Grifols Revenue in Hemophilia Drugs Business (2021-2026)
- 12.7.4 Grifols Hemophilia Drugs Product Portfolio
- 12.7.5 Grifols Recent Developments
- 12.8 F. Hoffmann-La Roche
- 12.8.1 F. Hoffmann-La Roche Company Information
- 12.8.2 F. Hoffmann-La Roche Business Overview
- 12.8.3 F. Hoffmann-La Roche Revenue in Hemophilia Drugs Business (2021-2026)
- 12.8.4 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio
- 12.8.5 F. Hoffmann-La Roche Recent Developments
- 12.9 Dimension Therapeutics
- 12.9.1 Dimension Therapeutics Company Information
- 12.9.2 Dimension Therapeutics Business Overview
- 12.9.3 Dimension Therapeutics Revenue in Hemophilia Drugs Business (2021-2026)
- 12.9.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio
- 12.9.5 Dimension Therapeutics Recent Developments
- 12.10 CSL Behring
- 12.10.1 CSL Behring Company Information
- 12.10.2 CSL Behring Business Overview
- 12.10.3 CSL Behring Revenue in Hemophilia Drugs Business (2021-2026)
- 12.10.4 CSL Behring Hemophilia Drugs Product Portfolio
- 12.10.5 CSL Behring Recent Developments
- 12.11 Catalyst Biosciences
- 12.11.1 Catalyst Biosciences Company Information
- 12.11.2 Catalyst Biosciences Business Overview
- 12.11.3 Catalyst Biosciences Revenue in Hemophilia Drugs Business (2021-2026)
- 12.11.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio
- 12.11.5 Catalyst Biosciences Recent Developments
- 12.12 BioMarin
- 12.12.1 BioMarin Company Information
- 12.12.2 BioMarin Business Overview
- 12.12.3 BioMarin Revenue in Hemophilia Drugs Business (2021-2026)
- 12.12.4 BioMarin Hemophilia Drugs Product Portfolio
- 12.12.5 BioMarin Recent Developments
- 12.13 Baxalta
- 12.13.1 Baxalta Company Information
- 12.13.2 Baxalta Business Overview
- 12.13.3 Baxalta Revenue in Hemophilia Drugs Business (2021-2026)
- 12.13.4 Baxalta Hemophilia Drugs Product Portfolio
- 12.13.5 Baxalta Recent Developments
- 12.14 Alnylam Pharmaceuticals
- 12.14.1 Alnylam Pharmaceuticals Company Information
- 12.14.2 Alnylam Pharmaceuticals Business Overview
- 12.14.3 Alnylam Pharmaceuticals Revenue in Hemophilia Drugs Business (2021-2026)
- 12.14.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
- 12.14.5 Alnylam Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst